ESMO 2026 | Mechanisms of resistance to ARPIs in prostate cancer

Name: Mechanisms of resistance to ARPIs in prostate cancer
Uploaded: 2026-10-26T00:00:00Z
Duration: 55 s

Alice Bernard-Tessier • 26 Oct 2026

ESMO 2026

Alice Bernard-Tessier, MD, Institut Gustave Roussy, Villejuif, France, discusses the mechanisms of resistance to androgen receptor pathway inhibitors (ARPIs), noting that approximately 60-80% of patients treated with ARPIs develop AR alterations, including amplification, mutation, and rearrangements. Dr Bernard-Tessier highlights that these alterations do not necessarily mean the tumor is no longer driven by the androgen receptor, and that the impact of these changes on novel AR-targeted drugs is still being explored. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.